Hello,

As many of you are likely aware, Akron pharmacetical's abrupt closure has put significant strain on the supply chain - particularly with eyedrops used for opthalmology procedures.

There is a growing body of literature from opthalmology organizations that support the use of multidose eye drops on multiple patients, provided that appropriately policies and procedures are in place to minimize risk of contamination to patients. Have any organizations acted on this and would be willing to share any guidance they have on how to approach this?